Penn. paying for counter-detailing
“If you just practice smart, you'll be able to give better care and, by the way, save money,” Avorn said. He first developed an academic detailing program 25 years ago while in medical school.
Takeda closes out a good-news, bad-news kind of week, AstraZeneca adds a new clinical trial for its experimental PD-1, and researchers link a funeral to the Ebola outbreak.
Evolocumab holds the FDA's first filed biologics license application for the class.
PwC anticipates that divestitures will fuel late-2014 deals, but notes that the noise around early deals and the financials don't fully match up.